Please Wait.....
Report
Europe Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher's Disease, MPS-1 & IV, Cancer, Alzheimer's Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
Market Report I 2022-11-18 I 222 Pages I The Insight Partners
The glycomic therapeutics market in Europe is expected to grow from US$ 37.00 billion in 2022 to US$ 88.66 billion by 2028; it is estimated to grow at a CAGR of 14.5% from 2022 to 2028.
Increasing Research and Development in Glycomic Therapeutics Drives Market Growth
Glycans may be exceedingly complex and are found in many areas of the microbiome components, such as proteins and cell surfaces. Researchers and players are actively involved in the glycomics industry and are constantly focusing on technological developments to offer better alternatives to conventional techniques. For instance, in March 2022, Palleon Pharmaceuticals, a company pioneering the field of glycol-immunology to treat cancer and inflammatory diseases, announced the dosing of the first patient in the company's Phase 1/2 study of E-602 in patients suffering from an advanced stage of cancers. The study, called GLIMMER-01 (Glycan-Immune Regulation), is the first clinical study of Palleon's novel approach to cancer immunotherapy, which targets immunosuppressive sialoglycans. In April 2022, CPTAC glycoproteomic researchers developed the "Peptide-First" multi-attribute glycan identification method. According to a study published in February 2022 by researchers at the University of Copenhagen's Center for Glycomics, Heparin can now be produced without using animal through glycomics studies. Such research and developments in the field of glycomics are driving the glycomics therapeutics market growth.
Market Overview
The Europe glycomic therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant share of the glycomic therapeutics market. Europe occupies a significant position in the glycomic therapeutics market and is estimated to register a robust growth rate over the forecast period. The market growth in the region is expected due to the rising number of cancer cases and viral infection and an increase in investment in research and development.
Europe Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Billion)
Europe Glycomic Therapeutics Market Segmentation
The Europe glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.
Based on class, the Europe glycomic therapeutics market is bifurcated into isolated and synthetic. The synthetic segment registered a larger market share in 2022. Based on structure, the Europe glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2022. Based on indications, the Europe glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher's disease, MPS-1 & IV, cancer, alzheimer's disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022. Based on mode of action, the Europe glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022. Based on country, the Europe glycomic therapeutics market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the market in 2022. IntellihepLtd; BioMarinPharmaceutical Inc.; GenzymeCorporation(Sanofi); BayerAG; Alzheon, Inc.; GlycoMar; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. are the leading companies operating in the glycomic therapeutics in Europe.
TABLE OF CONTENTS
1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Glycomic Therapeutics Market - By Class
1.3.2 Europe Glycomic Therapeutics Market - By Structures
1.3.3 Europe Glycomic Therapeutics Market - By Indications
1.3.4 Europe Glycomic Therapeutics Market - By Mode of Action
1.3.5 Europe Glycomic Therapeutics Market - By Country
2. Europe Glycomic Therapeutics Market- Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Glycomic Therapeutics Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Europe - PEST Analysis
4.3 Expert Opinion
5. Europe Glycomic Therapeutics Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Wide Application in Various Disorders Followed by the Development of New Treatment Processes
5.1.2 Increasing Research and Development In the Field of Glycomic Therapeutics
5.2 Market Restraints
5.2.1 Shortage of Skilled Professionals and Lack of Research & Development laboratories in Developing Countries.
5.3 Market Opportunities
5.3.1 Wide Applications of Glycomics in Therapeutics
5.4 Future Trends
5.4.1 New Tools in Glycomics Research
5.5 Impact Analysis
6. Glycomic Therapeutics Market- Europe Analysis
6.1 Europe Glycomic Therapeutics Market Revenue Forecast and Analysis
7. Europe Glycomic Therapeutics Market Revenue and Forecast to 2028- by Class
7.1 Overview
7.2 Europe Glycomic Therapeutics Market, By Class 2022 & 2028 (%)
7.2.1 Europe: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
7.3 Isolated
7.3.1 Overview
7.3.2 Europe Isolated Revenue and Forecast to 2028 (US$ Million)
7.4 Synthetic
7.4.1 Overview
7.4.2 Europe Synthetic - Revenue and Forecast to 2028 (US$ Million)
8. Europe Glycomics Therapeutics Market Analysis and Forecasts To 2028 - By Indication
8.1 Overview
8.2 Europe Glycomics Market, By Indication 2022 & 2028 (%)
8.2.1 Europe: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
8.3 Thrombosis and Chemoprophylaxis
8.3.1 Overview
8.3.2 Europe Thrombosis and chemoprophylaxis Revenue and Forecast to 2028 (US$ Million)
8.4 Anaemia
8.4.1 Overview
8.4.2 Europe Anaemia Revenue and Forecast to 2028 (US$ Million)
8.5 Anti-adhesive and Anti-inflammatory
8.5.1 Overview
8.5.2 Europe Anti-adhesive and Anti-inflammatory Revenue and Forecast to 2028 (US$ Million)
8.6 Cataract
8.6.1 Overview
8.6.2 Europe Cataract Revenue and Forecast to 2028 (US$ Million)
8.7 Gaucher's diseases
8.7.1 Overview
8.7.2 Europe Gaucher's diseases Revenue and Forecast to 2028 (US$ Million)
8.8 MPS-1 & IV
8.8.1 Overview
8.8.2 Europe MPS-1 & IV Revenue and Forecast to 2028 (US$ Million)
8.9 Cancer
8.9.1 Overview
8.9.2 Europe Cancer Revenue and Forecast to 2028 (US$ Million)
8.10 Alzheimer's
8.10.1 Overview
8.10.2 Europe Alzheimer's Revenue and Forecast to 2028 (US$ Million)
8.11 Influenza Type A and B
8.11.1 Overview
8.11.2 Europe Influenza Type A and B Revenue and Forecast to 2028 (US$ Million)
8.12 Others
8.12.1 Overview
8.12.2 Europe Others Revenue and Forecast to 2028 (US$ Million)
9. Europe Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Structures
9.1 Overview
9.2 Europe Glycomic Therapeutics Market, By Structures 2022 & 2028 (%)
9.2.1 Europe: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
9.2.1.1 Europe: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
9.2.1.2 Europe: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
9.2.1.3 Europe: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
9.2.1.4 Europe: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
9.3 Glycoproteins
9.3.1 Overview
9.3.2 Europe Glycoproteins - Market Revenue and Forecast to 2028 (US$ Million)
9.4 Targeting Sialic Acid
9.4.1 Overview
9.4.2 Europe Targeting Sialic Acid - Market Revenue and Forecast to 2028 (US$ Million)
9.4.3 Zanamivir
9.4.3.1 Overview
9.4.4 Europe Zanamivir - Market Revenue and Forecast to 2028 (US$ Million)
9.4.5 Oseltamivir
9.4.5.1 Overview
9.4.5.2 Europe Oseltamivir - Market Revenue and Forecast to 2028 (US$ Million)
9.5 Proteoglycans
9.5.1 Overview
9.5.2 Europe Proteoglycans - Market Revenue and Forecast to 2028 (US$ Million)
9.6 Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans
9.6.1 Overview
9.6.2 Europe Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecast to 2028 (US$ Million)
9.7 Targeting Glycosaminoglycans
9.7.1 Overview
9.7.2 Europe Targeting Glycosaminoglycans - Market Revenue and Forecast to 2028 (US$ Million)
9.7.3 Heparin
9.7.3.1 Overview
9.7.3.2 Europe Heparin - Market Revenue and Forecast to 2028 (US$ Million)
9.7.4 Hyaluronan (HA)
9.7.4.1 Overview
9.7.4.2 Europe Hyaluronan (HA)- Market Revenue and Forecast to 2028 (US$ Million)
9.7.5 Laronidase
9.7.5.1 Overview
9.7.5.2 Europe Laronidase - Market Revenue and Forecast to 2028 (US$ Million)
9.7.6 Galsulfase (Naglazyme)
9.7.6.1 Overview
9.7.6.2 Europe Galsulfase (Naglazyme) - Market Revenue and Forecast to 2028 (US$ Million)
9.7.7 Hyaluronidase (Cumulase)
9.7.7.1 Overview
9.7.7.2 Europe Hyaluronidase (Cumulase) - Market Revenue and Forecast to 2028 (US$ Million)
9.7.8 Others
9.7.8.1 Overview
9.7.8.2 Europe Others - Market Revenue and Forecast to 2028 (US$ Million)
9.8 Targeting Glycosphingolipids
9.8.1 Overview
9.8.2 Europe Targeting Glycosphingolipids - Market Revenue and Forecast to 2028 (US$ Million)
9.8.3 Imiglucerase (Cerezyme)
9.8.3.1 Overview
9.8.3.2 Europe Imiglucerase (Cerezyme)- Market Revenue and Forecast to 2028 (US$ Million)
9.8.3.3 Agalsidase (Fabrazyme)
9.8.3.3.1 Overview
9.8.3.3.2 Europe Agalsidase (Fabrazyme) - Market Revenue and Forecast to 2028 (US$ Million)
9.8.3.4 N-butyl-deoxynojirimycin (DNJ)
9.8.3.4.1 Overview
9.8.3.5 Europe N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecast to 2028 (US$ Million)
9.8.4 Others
9.8.4.1 Overview
9.8.4.2 Europe Others - Market Revenue and Forecast to 2028 (US$ Million)
9.9 Others
9.9.1 Overview
9.9.2 Europe Others - Market Revenue and Forecast to 2028 (US$ Million)
9.9.3 Acarbose
9.9.3.1 Overview
9.9.3.2 Europe Acarbose - Market Revenue and Forecast to 2028 (US$ Million)
9.9.3.3 Alglucosidase Alfa (Myozyme)
9.9.3.3.1 Overview
9.9.3.3.2 Europe Alglucosidase Alfa (Myozyme) - Market Revenue and Forecast to 2028 (US$ Million)
9.9.3.4 Allosamidin
9.9.3.4.1 Overview
9.9.3.4.2 Europe Allosamidin - Market Revenue and Forecast to 2028 (US$ Million)
9.9.4 Others
9.9.4.1 Overview
9.9.4.2 Europe Others - Market Revenue and Forecast to 2028 (US$ Million)
10. Europe Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Mode of Action
10.1 Overview
10.2 Europe Glycomic Therapeutics Market, By Mode of Action 2022 & 2028 (%)
10.2.1 Europe: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
10.3 Inhibits Neuraminidase
10.3.1 Overview
10.3.2 Europe Inhibits Neuraminidase - Market Revenue and Forecast to 2028 (US$ Million)
10.4 Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate
10.4.1 Overview
10.4.2 Europe Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecast to 2028 (US$ Million)
10.5 Erythropoietin And Enzyme Replacement Therapy (ERT)
10.5.1 Overview
10.5.2 Europe Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecast to 2028 (US$ Million)
10.6 Tissue Plasminogen Activator
10.6.1 Overview
10.6.2 Europe Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US$ Million)
10.7 Inhibits Glucosylceramide Synthase
10.7.1 Overview
10.7.2 Europe Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US$ Million)
10.8 Interleukin 1 And 2 And 3
10.8.1 Overview
10.8.2 Europe Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)
10.9 Beta And Gamma Interferons
10.9.1 Overview
10.9.2 Europe Beta And Gamma Interferons- Market Revenue And Forecasts To 2028 (US$ Million)
10.10 Others
10.10.1 Overview
10.10.2 Europe Others- Market Revenue And Forecasts To 2028 (US$ Million)
11. Europe Glycomic Therapeutics Market Revenue and Forecasts to 2028 - Country Analysis
11.1 Europe: Glycomic Therapeutics Market
11.1.1 Overview
11.1.2 Europe: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.3 Europe: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.3.1 Europe: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.3.2 Europe: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.3.3 Europe: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.3.4 Europe: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.4 Europe: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.5 Europe: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.6 Europe: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
11.1.6.1 Germany: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.1.1 Overview
11.1.6.1.2 Germany: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.1.3 Germany: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.6.1.4 Germany: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.6.1.4.1 Germany: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.6.1.4.2 Germany: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.6.1.4.3 Germany: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.6.1.4.4 Germany: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.6.1.5 Germany: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.6.1.6 Germany: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.6.2 UK: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.2.1 Overview
11.1.6.2.2 UK: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.2.3 UK: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.6.2.4 UK: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.6.2.4.1 UK: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.6.2.4.2 UK: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.6.2.4.3 UK: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.6.2.4.4 UK: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.6.2.5 UK: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.6.2.6 UK: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.6.3 France: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.3.1 Overview
11.1.6.3.2 France: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.3.3 France: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.6.3.4 France: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.6.3.4.1 France: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.6.3.4.2 France: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.6.3.4.3 France: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.6.3.4.4 France: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.6.3.5 France: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.6.3.6 France: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.6.4 Italy: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.4.1 Overview
11.1.6.4.2 Italy: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.4.3 Italy: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.6.4.4 Italy: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.6.4.4.1 Italy: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.6.4.4.2 Italy: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.6.4.4.3 Italy: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.6.4.4.4 Italy: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.6.4.5 Italy: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.6.4.6 Italy: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.6.5 Spain: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.5.1 Overview
11.1.6.5.2 Spain: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.5.3 Spain: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.6.5.4 Spain: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.6.5.4.1 Spain: Glycomic Therapeutics Market, by Targeting Glycosphingolipid, 2019-2028 (US$ Million)
11.1.6.5.4.2 Spain: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.6.5.4.3 Spain: Glycomic Therapeutics Market, by Targeting Glycosaminoglycans, 2019-2028 (US$ Million)
11.1.6.5.4.4 Spain: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.6.5.5 Spain: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.6.5.6 Spain: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.6.6 Rest of Europe: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.6.1 Overview
11.1.6.6.2 Rest of Europe: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.6.6.3 Rest of Europe: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.6.6.4 Rest of Europe: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.6.6.4.1 Rest of Europe: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.6.6.4.2 Rest of Europe: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.6.6.4.3 Rest of Europe: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.6.6.4.4 Rest of Europe: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.6.6.5 Rest of Europe: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.6.6.6 Rest of Europe: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
12. Glycomic Therapeutics Market -Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Glycomic Therapeutics Market (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 Intellihep Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 BioMarin Pharmaceutical Inc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Genzyme Corporation (Sanofi)
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bayer AG
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 GlycoMar
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 GlaxoSmithKline plc.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 F. Hoffmann-La Roche Ltd
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms in Glycomic Therapeutics Market
LIST OF TABLES
Table 1. Europe Glycomic Therapeutics Market, by C lass - Revenue and Forecast to 2028 (US$ Million)
Table 2. Europe Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (USD Million)
Table 3. Europe Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (USD Million)
Table 4. Europe Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (USD Million)
Table 5. Europe Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (USD Million)
Table 6. Europe Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (USD Million)
Table 7. Europe Glycomic Therapeutics Market, by Others- Revenue and Forecast to 2028 (USD Million)
Table 8. Europe Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (USD Million)
Table 9. Europe Glycomic Therapeutics Market, by C lass - Revenue and Forecast to 2028 (US$ Million)
Table 10. Europe Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (USD Million)
Table 11. Europe Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (USD Million)
Table 12. Europe Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (USD Million)
Table 13. Europe Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (USD Million)
Table 14. Europe Glycomic Therapeutics Market, by Others- Revenue and Forecast to 2028 (USD Million)
Table 15. Europe Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (USD Million)
Table 16. Europe Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (USD Million)
Table 17. Germany Glycomic Therapeutics Market, by Class - Revenue and Forecast to 2028 (US$ Million)
Table 18. Germany Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (US$ Million)
Table 19. Germany Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (US$ Million)
Table 20. Germany Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (US$ Million)
Table 21. Germany Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (US$ Million)
Table 22. Germany Glycomic Therapeutics Market, by Others - Revenue and Forecast to 2028 (US$ Million)
Table 23. Germany Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 24. Germany Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (US$ Million)
Table 25. UK Glycomic Therapeutics Market, by Class - Revenue and Forecast to 2028 (US$ Million)
Table 26. UK Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (US$ Million)
Table 27. UK Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (US$ Million)
Table 28. UK Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (US$ Million)
Table 29. UK Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (US$ Million)
Table 30. UK Glycomic Therapeutics Market, by Others - Revenue and Forecast to 2028 (US$ Million)
Table 31. UK Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 32. UK Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (US$ Million)
Table 33. France Glycomic Therapeutics Market, by Class - Revenue and Forecast to 2028 (US$ Million)
Table 34. France Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (US$ Million)
Table 35. France Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (US$ Million)
Table 36. France Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (US$ Million)
Table 37. France Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (US$ Million)
Table 38. France Glycomic Therapeutics Market, by Others - Revenue and Forecast to 2028 (US$ Million)
Table 39. France Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 40. France Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (US$ Million)
Table 41. Italy Glycomic Therapeutics Market, by Class - Revenue and Forecast to 2028 (US$ Million)
Table 42. Italy Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (US$ Million)
Table 43. Italy Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (US$ Million)
Table 44. Italy Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (US$ Million)
Table 45. Italy Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (US$ Million)
Table 46. Italy Glycomic Therapeutics Market, by Others - Revenue and Forecast to 2028 (US$ Million)
Table 47. Italy Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 48. Italy Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (US$ Million)
Table 49. Spain Glycomic Therapeutics Market, by Class - Revenue and Forecast to 2028 (US$ Million)
Table 50. Spain Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (US$ Million)
Table 51. Spain Glycomic Therapeutics Market, by Targeting Glycosphingolipid - Revenue and Forecast to 2028 (US$ Million)
Table 52. Spain Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (US$ Million)
Table 53. Spain Glycomic Therapeutics Market, by Targeting Glycosaminoglycans - Revenue and Forecast to 2028 (US$ Million)
Table 54. Spain Glycomic Therapeutics Market, by Others - Revenue and Forecast to 2028 (US$ Million)
Table 55. Spain Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 56. Spain Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (US$ Million)
Table 57. Rest of Europe Glycomic Therapeutics Market, by Class - Revenue and Forecast to 2028 (US$ Million)
Table 58. Rest of Europe Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (US$ Million)
Table 59. Rest of Europe Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (US$ Million)
Table 60. Rest of Europe Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (US$ Million)
Table 61. Rest of Europe Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (US$ Million)
Table 62. Rest of Europe Glycomic Therapeutics Market, by Others - Revenue and Forecast to 2028 (US$ Million)
Table 63. Rest of Europe Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 64. Rest of Europe Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (US$ Million)
Table 65. Organic Developments in the Glycomic Therapeutics Market
Table 66. Inorganic Developments in the Glycomic Therapeutics Market
Table 67. Glossary of Terms in Glycomic Therapeutics Market
LIST OF FIGURES
Figure 1. Europe Glycomic Therapeutics Market Segmentation
Figure 2. Europe Glycomic Therapeutics Market, By Country
Figure 3. Europe Glycomic Therapeutics Market Overview
Figure 4. Synthetic Segment Held Largest Share of Class Segment in Europe Glycomic Therapeutics Market
Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Europe: PEST Analysis
Figure 7. Europe Glycomic Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. Europe Glycomics market - Revenue Forecast And Analysis - 2020- 2028
Figure 9. Europe Glycomic Therapeutics Market, by Class 2022 & 2028 (%)
Figure 10. Europe Isolated Revenue and Forecasts to 2028 (US$ Million)
Figure 11. Europe Synthetic - Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Europe Glycomics Market, by Indication 2022 & 2028 (%)
Figure 13. Europe Thrombosis and chemoprophylaxis Revenue and Forecasts to 2028 (US$ Million)
Figure 14. Europe Anaemia Revenue and Forecasts to 2028 (US$ Million)
Figure 15. Europe Anti-adhesive and Anti-inflammatory Revenue and Forecasts to 2028 (US$ Million)
Figure 16. Europe Cataract Revenue and Forecasts to 2028 (US$ Million)
Figure 17. Europe Gaucher's diseases Revenue and Forecasts to 2028 (US$ Million)
Figure 18. Europe MPS-1 & IV Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Europe Cancer Revenue and Forecasts to 2028 (US$ Million)
Figure 20. Europe Alzheimer's Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Europe Influenza Type A and B Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Europe Others Revenue and Forecasts to 2028 (US$ Million)
Figure 23. Europe Glycomic Therapeutics Market, by Structures 2022 & 2028 (%)
Figure 24. Europe Glycoproteins - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 25. Europe Targeting Sialic Acid - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 26. Europe Zanamivir - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 27. Europe Oseltamivir - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 28. Europe Proteoglycans - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 29. Europe Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 30. Europe Targeting Glycosaminoglycans - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 31. Europe Heparin - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 32. Europe Hyaluronan (HA) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 33. Europe Laronidase - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 34. Europe Galsulfase (Naglazyme) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 35. Europe Hyaluronidase (Cumulase) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 36. Europe Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 37. Europe Targeting Glycosphingolipids - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 38. Europe Imiglucerase (Cerezyme - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 39. Europe Agalsidase (Fabrazyme) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 40. Europe N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 41. Europe Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 42. Europe Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 43. Europe Acarbose - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 44. Europe Alglucosidase Alfa (Myozyme) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 45. Europe Allosamidin - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 46. Europe Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 47. Europe Glycomic Therapeutics Market, by Mode of Action 2022 & 2028 (%)
Figure 48. Europe Inhibits Neuraminidase - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 49. Europe Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 50. Europe Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 51. Europe Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 52. Europe Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 53. Europe Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)
Figure 54. Europe Beta And Gamma Interferons - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 55. Europe Others - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 56. Europe: Glycomic Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 57. Europe: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
Figure 58. Germany: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 59. UK: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 60. France: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 61. Italy: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 62. Spain: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 63. Rest of Europe: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 64. Growth Strategies in the Glycomic Therapeutics Market (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security